Article

FDA Briefs - March 1, 2002

Allergan's brimonidine tartrate (Alphagan) will have new labeling that indicates its 0.5% strength is suitable for pediatric patients over 2 years old.

Related Videos
Image credit: Ophthalmology Times; Dean McGee Eye Institute resident Ashley Ooms, MD, explores gray area strabismus surgery complications in AUPO poster
J. Peter Campbell, MD, MPH
Expanding accessibility of vision correction with spectacles for children with cranial abnormalities
Elkin: Talking about the importance of pediatric eye health and safety
Identifying 3 barriers keeping families from accessing cataract treatment for their children in India
Related Content
Hyperacute outer retinal dysfunction may be an underrecognized pediatric disorder
February 22nd 2025

Hyperacute outer retinal dysfunction may be an underrecognized pediatric disorder

ROP: Treating and preventing blindness in preterm babies
October 18th 2021

ROP: Treating and preventing blindness in preterm babies

Vyluma announces NMPA of China accepts drug application of NVK002 (low-dose atropine 0.01%) for myopia progression in children
January 30th 2025

Vyluma announces NMPA of China accepts drug application of NVK002 (low-dose atropine 0.01%) for myopia progression in children

Managing a changing landscape of IRD pediatric cases
May 10th 2021

Managing a changing landscape of IRD pediatric cases

Microdrops show promise for safer retinopathy of prematurity screening in preterm infants
January 3rd 2025

Microdrops show promise for safer retinopathy of prematurity screening in preterm infants

4-Year research validates DOT 0.2 spectacle lenses as early myopia treatment
December 12th 2024

4-Year research validates DOT 0.2 spectacle lenses as early myopia treatment

© 2025 MJH Life Sciences

All rights reserved.